A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Summary

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

Timeline

Start

2019-01-23

Primary completion

2022-03-24

Completion

2022-03-24

Publications

• Lugrin C, Alecci L, Simillion C, Volkova-Volkmar E, Giboin LS, Kinsella FC, McColgan P, Wild EJ, Dorn J. Longitudinal assessment of chorea in Huntington's disease using digital passive monitoring. NPJ Digit Med. 2026 Apr 25;9(1):495. doi: 10.1038/s41746-026-02661-y.
• Rodrigues FB, Ferreira JJ, Wild EJ. Huntington's Disease Clinical Trials Corner: June 2019. J Huntingtons Dis. 2019;8(3):363-371. doi: 10.3233/JHD-199003.
• Rodrigues FB, Quinn L, Wild EJ. Huntington's Disease Clinical Trials Corner: January 2019. J Huntingtons Dis. 2019;8(1):115-125. doi: 10.3233/JHD-190001.

Drugs

Indications